Startseite Kongressberichte 2021 EHA2021 Virtual Congress Lymphoma Aggressive lymphoma - Combination therapies

Aggressive lymphoma - Combination therapies

Overview of Presentations with access to videos on demand (EHA subscription needed) 


The study authors conclude that in this large Dutch population of young patients with advanced ALCL, AITL or PTCL NOS, the use of ASCT consolidation, regardless of the addition of etoposide to CHOP, significantly improved overall survival and could explain the survival benefit in the last decade. The authors finally conclude that this nationwide population-based study corroborates other independent studies suggesting CHO(E)P followed by ASCT as a first-line therapeutic regimen for young and fit T- NHL patients.


The study authors conclude that rituximab in addition to standard LMB therapy achieved outstanding event-free and overall survival in both randomized and additional parts of the trial in children/adolescents with high-risk B-NHL/AL with significant acute toxicity and hypoglobulinemia. However, some very rare patients still have resistant disease and very poor outcome, notably those with Burkitt lymphoma.


The study authors conclude that their data indicate that M-Pola has an acceptable safety profile, with no Gr ≥2 CRS observed, and promising efficacy in pts with R/R NHL with predominantly aggressive disease.


The study authors conclude that the R2-MTX regimen is a feasible and active combination treatment for newly diagnosed PCNSL patients. It demonstrates excellent response rate, as well as good tolerability. More clinical data will be updated from this ongoing study (NCT04120350).


The study authors conclude that in their large multi-institutional database study, the 4-year overall survival was similar between R-CHOP and R-EPOCH among MYC-R DLBCL and DHL/THL. In multivariable analysis, ECOG ≥2 and elevated LDH were the only variables independently associated with poor prognosis in this subgroup. Most deaths occurred within 2y of diagnosis, with similar overall survival in both arms at 4y.